IRL-1620 is a potent and selectiveendothelin receptortype B (ETB)agonist with aK_iof 16 pM.

IRL-1620 is the most potent and specific ligand for the ETB receptor (K_iETA/ K_iETB=120,000) as judged by the K_ivalues for ETA (19 μM) and ETB (16 PM) receptors^[1].
IRL-1620 is 60 times more selective for the ETB receptor than ET-3 (K_iETA/ K_iETB=1,900)^[1].

IRL-1620 (1-100 nM) induces contractions of the guinea pig trachea. The effective concentration that produces 30 % of 60 mM KCI-induced contraction is estimated to be 28 nM for IRL 1620^[1].
IRL-1620 (1-100 nM) increases cytosolic Ca²⁺in the vascular endothelium ([Ca]E) with little effect on resting muscle tone, and relaxes the norepinephrine-stimulated tone with an increase in [Ca]E, in rat aorta,^[1].
IRL-1620 improves both acquisition (learning) and retention (memory) on the water maze task and enhances angiogenic and neurogenic remodeling. Rats treated with IRL-1620 significantly reduces the cognitive impairment induced by Aβ. IRL-1620 treatment enhances the number of blood vessels labeled with VEGF compared to vehicle treatment^[2].
IRL-1620, restores analgesic tolerance to morphine and oxycodone, but it does not affect morphine and oxycodone induced decrease in NGF/PI3K expression. IRL-1620 attenuates opioid tolerance without the involvement of NGF/PI3K pathway^[3].

1820.95

C₈₆H₁₁₇N₁₇O₂₇

142569-99-1

{Suc}-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp

{Suc}-DEEAVYFAHLDIIW

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.